CLINICAL TRIALS PROFILE FOR MEKINIST
✉ Email this page to a colleague
All Clinical Trials for MEKINIST
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT01438554 ↗ | Phase 1 Study of Pazopanib With GSK1120212 in Advanced Solid Tumors, Enriched With Patients With Differentiated Thyroid Cancer, Soft-tissue Sarcoma, and Cholangiocarcinoma | Completed | GlaxoSmithKline | Phase 1 | 2011-10-01 | The purpose of this study is to determine the safety and toxicity of the combination of pazopanib and GSK1120212 in patients with solid tumors and identify the maximum tolerated dose (MTD) of this combination for phase II study. |
| NCT01438554 ↗ | Phase 1 Study of Pazopanib With GSK1120212 in Advanced Solid Tumors, Enriched With Patients With Differentiated Thyroid Cancer, Soft-tissue Sarcoma, and Cholangiocarcinoma | Completed | National Comprehensive Cancer Network | Phase 1 | 2011-10-01 | The purpose of this study is to determine the safety and toxicity of the combination of pazopanib and GSK1120212 in patients with solid tumors and identify the maximum tolerated dose (MTD) of this combination for phase II study. |
| NCT01438554 ↗ | Phase 1 Study of Pazopanib With GSK1120212 in Advanced Solid Tumors, Enriched With Patients With Differentiated Thyroid Cancer, Soft-tissue Sarcoma, and Cholangiocarcinoma | Completed | Novartis | Phase 1 | 2011-10-01 | The purpose of this study is to determine the safety and toxicity of the combination of pazopanib and GSK1120212 in patients with solid tumors and identify the maximum tolerated dose (MTD) of this combination for phase II study. |
| NCT01438554 ↗ | Phase 1 Study of Pazopanib With GSK1120212 in Advanced Solid Tumors, Enriched With Patients With Differentiated Thyroid Cancer, Soft-tissue Sarcoma, and Cholangiocarcinoma | Completed | Sidney Kimmel Comprehensive Cancer Center | Phase 1 | 2011-10-01 | The purpose of this study is to determine the safety and toxicity of the combination of pazopanib and GSK1120212 in patients with solid tumors and identify the maximum tolerated dose (MTD) of this combination for phase II study. |
| NCT01438554 ↗ | Phase 1 Study of Pazopanib With GSK1120212 in Advanced Solid Tumors, Enriched With Patients With Differentiated Thyroid Cancer, Soft-tissue Sarcoma, and Cholangiocarcinoma | Completed | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 1 | 2011-10-01 | The purpose of this study is to determine the safety and toxicity of the combination of pazopanib and GSK1120212 in patients with solid tumors and identify the maximum tolerated dose (MTD) of this combination for phase II study. |
| NCT01553851 ↗ | GSK1120212 in Surgically Resectable Oral Cavity Squamous Cell Cancer | Completed | National Comprehensive Cancer Network | Phase 2 | 2013-02-01 | This phase II trial studies how trametinib effects tumor cells in patients with oral cavity squamous cell carcinoma that can be removed by surgery. Trametinib may shrink the tumor by blocking an enzyme pathway needed for cell growth. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for MEKINIST
Condition Name
Clinical Trial Locations for MEKINIST
Trials by Country
Clinical Trial Progress for MEKINIST
Clinical Trial Phase
Clinical Trial Sponsors for MEKINIST
Sponsor Name
